PK
Paul D. Kessler
SVP Clinical, Med. & Reg.; CMO

Paul D. Kessler insider trades: Nabi Biopharmaceuticals (NABI) stock sales

SVP Clinical, Med. & Reg.; CMO, Nabi Biopharmaceuticals Last trade Apr 5, 2012 12 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
9
Open-market trades
since 2008
1
Company
last trade 2012

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Paul reports to the SEC

Open-market buys and sales

9 trades reported on SEC Form 4, newest first

DateStockTypeValue
Apr 5, 2012NABI↓ Sell$10K
May 16, 2011NABI↓ Sell10b5-1$68K
Apr 5, 2011NABI↓ Sell$49K
Jan 5, 2011NABI↓ Sell10b5-1$17K
May 17, 2010NABI↓ Sell$86K
Apr 5, 2010NABI↓ Sell$28K
Nov 23, 2009NABI↓ Sell$3K
Nov 20, 2009NABI↓ Sell$89K
Mar 5, 2008NABI↓ Sell$12K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Paul D. Kessler's insider trades

Paul D. Kessler is SVP Clinical, Med. & Reg.; CMO at Nabi Biopharmaceuticals (NABI). Since Mar 5, 2008, Paul has reported no open-market purchases and 9 sales worth $362K on SEC Form 4. There have been no open-market trades in the last 12 months.

2 sales (24% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.

Their filings also include grants and awards (4 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NABI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.